Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201401085 Principal Investigator: Romee, Rizwan
Title: A phase 1 study of cytokine-induced memory-like allogeneic NK cells in patients with relapsed and refractory AML
Description: The purpose of this research study is to discover the side effects and highest dose of a treatment for AML called CIML NK cells. NK cells, or natural killer cells, are cells found in your bloodstream whose function is to fight infection and tumor cells....MORE
___________________________________________________________________________________________________
 Number: 201401080 Principal Investigator: Romee, Rizwan
Title: A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation with High Dose PT-Cy in Relapsed/Refractory AML
Description: The purpose of this research study is to look at patient's overall health status and how their disease responds to a stem cell transplant when followed with several doses of a drug called cyclophosphamide....MORE
___________________________________________________________________________________________________
 Number: 201309091 Principal Investigator: Jacoby, Meagan
Title: A Phase I Study of Vosaroxin plus Azacitidine for Patients with Myelodysplastic Syndrome
Description: The purpose of this research study is to evaluate the safety and side effects of treating MDS with a combination of two drugs, azacitidine and vosaroxin....MORE
___________________________________________________________________________________________________
 Number: 201303012 Principal Investigator: Schroeder, Mark
Title: Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Description: This research study aims to discover the side effects and highest dose of a drug called azacitidine that can be given after a stem cell transplant to help prevent or minimize the effects of graft-versus-host disease (GVHD). We will also look at the way azacitidine might affect whether or how a pers...MORE
___________________________________________________________________________________________________
 Number: 201210102 Principal Investigator: Welch, John
Title: Genomic Predictors of Decitabine Response in AML/MDS
Description: The purpose of this research study is to identify genetic markers which will help us predict who will respond to treatment with a drug called decitabine and who will not. Typically, between 20 and 30% of patients with AML and MDS will achieve a complete response with decitabine, while the remaining...MORE
___________________________________________________________________________________________________
 Number: 201402089 Principal Investigator: Romee, Rizwan
Title: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
Description: The purpose of this research study is to determine optimal (best) dose of ALT-803 (the investigational drug) either at the maximum tolerated dose (MTD) or the minimal effective dose (MED), which ever dose level is found first. Other objectives of this study are to find out the side effects associat...MORE
___________________________________________________________________________________________________
 Number: 201303028 Principal Investigator: Westervelt, Peter
Title: A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Description: This study will evaluate the safety of administration of the investigational cord blood units....MORE
___________________________________________________________________________________________________
 Number: 201102463 Principal Investigator: Fehniger, Todd
Title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Description: This study is investigating a newer donor selection factor, KIR genotyping, in addition to HLA testing and other donor selection factors....MORE
___________________________________________________________________________________________________
 Number: CTSU E2906 Principal Investigator: Uy, Geoffrey
Title: Phase III Randomized Trial of Clofarabine as Induction and Post- Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >= 60 Years)
Description: This trial is studying clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia....MORE
___________________________________________________________________________________________________
 Number: CTSU CIRB S1203 Principal Investigator: Uy, Geoffrey
Title: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Description: The purpose of this study is to compare the effects, good and/or bad of three drug combinations. We want to see if the study treatments will get rid of leukemia cells and keep them from coming back to prepare a patient who may benefit from stem cell transplant....MORE
___________________________________________________________________________________________________
 Number: CALGB E1912 Principal Investigator: Bartlett, Nancy
Title: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Description: The purpose of this study is to compare the effects, good and/or bad, of two different therapies that include combinations of the drugs rituximab, fludarabine, cyclophosphamide and Ibrutinib have on you and your CLL. The first three of these drugs are standard treatments for CLL. Fludarabine and cyc...MORE
___________________________________________________________________________________________________
 Number: CALGB E1910 Principal Investigator: Uy, Geoffrey
Title: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL negative B lineage Acute Lymphoblastic Leukemia in Adults
Description: This study in being done to determine what affects (good and bad) the therapy blinatumomab has on your type of cancer (BCR/ABL negative ALL). This new therapy will be added to what has traditionally been used to treat your specific sub-type of ALL....MORE
___________________________________________________________________________________________________
 Number: CALGB A041202 Principal Investigator: Bartlett, Nancy
Title: A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Description: The purpose of this study is to compare the effects, good and/or bad, of the drug ibrutinib, either alone or in combination with the drug rituximab, with the standard treatment for this disease. The standard treatment is chemotherapy with the drug bendamustine in combination with the drug rituxima...MORE
___________________________________________________________________________________________________
 Number: BMT CTN 1203 Principal Investigator: Pusic, Iskra
Title: A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
Description: The purpose of this research study is to compare three combinations of medications to see whether one or more of them are better than the current standard of care (Tacrolimus/Methotrexate) to prevent GVHD(Graft-versus-Host Disease). These combinations of medication in this study are: Treatment Gro...MORE
___________________________________________________________________________________________________
 Number: BMT CTN 1102 Principal Investigator: Westervelt, Peter
Title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome
Description: The purpose of this research study is to find out if a reduced-intensity transplant works better than the standard treatment for Myelodysplastic Syndrome (MDS). We also want to know how well you are able to do your normal activities after your treatment....MORE
___________________________________________________________________________________________________
 Number: 201407131 Principal Investigator: Wagner-Johnston, Nina
Title: A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Description: The purpose of this research study is to compare the effects, good or bad of an investigational drug called IPI-145 with those of a drug called ofatumumab on you and your chronic lymphocytic leukemia (CLL) cancer or small lymphocytic leukemia (SLL) cancer to find out which is better....MORE
___________________________________________________________________________________________________
 Number: 201406070 Principal Investigator: Jacoby, Meagan
Title: A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndromes (MDS)
Description: The purpose of this study is to test if treatment with eltrombopag and azacitidine can decrease the need forplatelet transfusions....MORE
___________________________________________________________________________________________________
 Number: 201406064 Principal Investigator: Wagner-Johnston, Nina
Title: A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion
Description: The purpose of this research study is to provide more information about whether giving rituximab and IDELA (an investigational drug) together can benefit patients with CLL who have a 17p deletion. All cells in the body receive signals to grow and survive, but sometimes these signals get out of contr...MORE
___________________________________________________________________________________________________
 Number: 201403069 Principal Investigator: Uy, Geoffrey
Title: A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Description: The purpose of this research study is to see if quizartinib, an investigational drug,is effective when it is compared to standard forms of chemotherapy used in treating patients with AML....MORE
___________________________________________________________________________________________________
 Number: 201402042 Principal Investigator: Uy, Geoffrey
Title: A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Description: The purpose of this trial is to determine the maximum dose of MGD006, further our understanding of possible side-effects and evaluate the effectiveness of MGD006 in treating AML....MORE
___________________________________________________________________________________________________
 Number: 201311132 Principal Investigator: Abboud, Camille
Title: A Phase II, randomized, comparative trial of standard of care, with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD mutated acute myeloid leukemia
Description: The purpose of this study is to find out if the addition of a drug called midostaurin (PKC412) given to patients with acute myeloid leukemia (AML) that have a FLT3-ITD mutation and have received an allogeneic stem cell transplant (SCT) can reduce the risk of relapse or having the disease reappear....MORE
___________________________________________________________________________________________________
 Number: 201310115 Principal Investigator: Ghobadi, Armin
Title: A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
Description: This study will compare blinatumomab to the standard of care chemotherapy that patients would normally receive to find out which treatment works best to treat Philadelphia negative Acute Lymphoblastic Leukemia....MORE
___________________________________________________________________________________________________
 Number: 201309078 Principal Investigator: Ghobadi, Armin
Title: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)
Description: The purpose of this research study is to see how well blinatumomab treats relapsed/refractory Philadelphia positive Acute Lymphoblastic Leukemia and whether it causes any side effects....MORE
___________________________________________________________________________________________________
 Number: 201308060 Principal Investigator: Uy, Geoffrey
Title: An open label, Phase I/IIa, dose escalation trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of volasertib in combination with decitabine in patients >65 years with acute myeloid leukemia
Description: This study will investigate how well a new drug called volasertib (BI 6727) works when used in combination with decitabine (Dacogen®) in adult patients with AML. The study will also investigate the possible side effects of the drug. ...MORE
___________________________________________________________________________________________________
 Number: 201307074 Principal Investigator: Stockerl-Goldstein, Keith
Title: A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Description: The purpose of this research study is to find out if MLN9708 plus dexamethasone works against systemic light chain amyloidosis better than the physician’s choice chemotherapy treatment....MORE
___________________________________________________________________________________________________
 Number: 201205111 Principal Investigator: Fehniger, Todd
Title: A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Description: This study is being done to evaluate a drug called CNDO-109 Activated Allogeneic Natural Killer Cells and how patients with Acute Myeloid Leukemia (AML) respond when given this therapy....MORE
___________________________________________________________________________________________________
 Number: 201301154 Principal Investigator: Dehdashti, Farrokh
Title: Imaging of Patients after Infusion of Haploidentical Genetically Modified T cells: A Pilot Study of Tracking and Toxicity and a companion to the protocol: “TK008: Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia
___________________________________________________________________________________________________
 Number: 201011766 Principal Investigator: Westervelt, Peter
Title: Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases
___________________________________________________________________________________________________
 Number: 201102097 Principal Investigator: DiPersio, John
Title: Part I of an Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related Disorders
___________________________________________________________________________________________________